A Phase 3 Registration Trial of PXL065 for the Treatment of Noncirrhotic Biopsy-Proven NASH Patients
Latest Information Update: 23 Sep 2021
At a glance
- Drugs Pioglitazone deuterated (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Registrational
- Sponsors Poxel
Most Recent Events
- 21 Sep 2021 According to a Poxel media release, results from DESTINY 1 trial should allow us to select one (or potentially two) doses that could then be studied in this confirmatory pivotal trial.
- 17 Nov 2019 New trial record
- 08 Nov 2019 According to Poxel media release, the company is planning to initiate this study in 2Q 2020.